Tue, Jul 22, 2014, 4:45 PM EDT - U.S. Markets closed

Recent

% | $
Click the to save as a favorite.

Genomic Health Inc. Message Board

terry_amln 26 posts  |  Last Activity: Jun 18, 2014 2:52 AM Member since: Oct 25, 2010
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • terry_amln terry_amln Jun 18, 2014 2:52 AM Flag

    e.g.:" terryamln Jun 15 • "Total and complete control of this board. I love it!"
    ....You must be so Proud!

  • terry_amln terry_amln Jun 18, 2014 2:49 AM Flag

    "terryamln" is of course kvncmncdd and fudfighter4 and are clown wanna bes.The GHDX msg bd is also spammed the same way. 40 posts of spam on 2 boards ... they are surely kids.

  • Major owner of Genomic Health was just granted 20,000 options ( Baker- Felix)
    as did everyone else - strike -27.75 price

  • Genomic Health Announces Positive Topline Results of Second Large, Independent Validation Study of Oncotype in DCIS Breast Cancer
    GHDX) today announced positive preliminary results from a second large, independent clinical validation study of Oncotype DX in patients with a pre-invasive form of breast cancer, also known as DCIS (ductal carcinoma in situ). The study, conducted by the Ontario DCIS Study Group in Canada, met its primary endpoint by demonstrating that the Oncotype DX DCIS Score™ predicts the risk of local recurrence, defined as either the development of a new invasive breast cancer or the recurrence of DCIS in the same breast.

    Representing the largest genomic study in DCIS to date, these results confirm and extend the conclusions of the previously published validation study performed by the ECOG-ACRIN Cancer Research Group. Additionally, for the first time, the Oncotype DX DCIS Score predicted the risk of local recurrence in a group of patients treated with radiation therapy in clinical practice. Genomic Health and the Ontario DCIS Study Group are submitting the results from this study for presentation at the 2014 San Antonio Breast Cancer Symposium in December.

    "It is widely recognized that a large proportion of women with DCIS are treated with a limited ability to quantify risk associated with the patient's underlying tumor biology," said Eileen Rakovitch, M.D., radiation oncologist and principal investigator, Sunnybrook Health Sciences Centre, Canada. "Our landmark study, analyzing an unprecedented collection of DCIS tissue samples representative of a contemporary patient population, confirms that the Oncotype DX test can help individualize treatment decisions for this pre-invasive type of breast cancer."

  • Multiple studies presented at 2014 ASCO annual meeting reinforce unique, practice-changing value of Oncotype DX® breast cancer test
    Demonstrate importance of consistent results from multiple validation studies
    Highlight substantial differences between multi-gene tests
    Reinforce Genomic Healthâ#$%$™s commitment to improving the quality of treatment decisions for cancer patients
    GENEVA, Switzerland--(BUSINESS WIRE)-- Genomic Health, Inc. (Nasdaq: GHDX) announced results of three studies with the Oncotype DX breast cancer test at the recent 2014 American Society of Clinical Oncology® (ASCO®) Annual Meeting.

  • terry_amln terry_amln Jun 2, 2014 8:47 AM Flag

    Since GHDX did the stock buyback the only thing the Baker bros want is more shares. (46% of the shares) until they get to 49.9999 % of the company. Felix and co dont care what the price is ( they were buying last year at $36) - they only care the price the company gets sold for. Good Luck

  • Multiple Studies Presented at ASCO Annual Meeting Demonstrate Unique, Practice-Changing Impact of Oncotype DX to Optimize Cancer Care
    GHDX) today announced results of six studies being presented at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 30 - June 3 in Chicago, underscoring the practice-changing value of Oncotype DX in pre-invasive and invasive breast cancer and colon cancer.

    The presentations include the first Oncotype DX DCIS Scoreâ„¢ clinical decision impact study, which showed a 31 percent change in treatment recommendations. Additionally, a direct comparison study of the Oncotype DX breast cancer test and the ROR score confirmed that the assays are not the same and that the information they provide is not equivalent.

  • GHDX today announced results of a large, positive study that confirmed that the Oncotype DX® test results for Recurrence Score® and quantitative estrogen-receptor (ER) predict late distant recurrence risk in early-stage breast cancer patients after initial tamoxifen therapy, suggesting that Oncotype DX may help identify which patients have greater potential to benefit from extended hormonal treatment beyond five years.  One of the nine Oncotype DX studies being presented at the 2014 American Society of Clinical Oncology Annual Meeting taking place in Chicago, these data will be presented on June 2 at 8:00 a.m. Central Time.

    "As recognized by ASCO's guideline update, recent studies have shown that extending tamoxifen treatment for 10 years is associated with better outcomes, however, we still need better tools to identify who those patients are," said Norman Wolmark, M.D., chairman of the National Surgical Adjuvant Breast and Bowel Project (NSABP). "This study confirms that Oncotype DX can help better define who is at greatest risk for late recurrences and the potential to benefit from extended tamoxifen, as well as those who are at lower risk and will likely have less absolute benefit from extended tamoxifen and, thus, could be spared prolonged exposure and risk of long-term side effects."

    This new study analyzed 668 and 1065 patients from the original NSABP B-14 and B-28 trials, respectively. Median follow-up of 13.9 years (B-14) and 11.2 years (B-28) determined that the Oncotype DX Recurrence Score results were significantly associated with distant recurrence after five years in patients whose tumors had high estrogen receptor expression. Specifically, in the NSABP B-14 patients, the association of the continuous Recurrence Score with distant recurrence after five years in the higher

  • terry_amln by terry_amln May 20, 2014 6:08 PM Flag

    From the folks who brought you "transition!" and canned the Chief Medical officier comes a cleverly hidden in the PR is the notice that **" In the next several months,*** the Company plans to incorporate the trial results into discussions with the regulatory agencies in the United States and Europe to determine next steps for ARIKAYCE in the treatment of NTM lung infections.
    Ah ! take a trip down memory lane...1st Qtr! discussions end with regulatory "by second quarter "... and on and on.Insmed did not say 2017 ?? for nothing. YTD +86% on INSM and waiting for the smoke to clear, make no mistake today was smoke and mirrors trading

  • Reply to

    Late breaking abstract: 91% reenrollment

    by jsblvbjb May 18, 2014 2:58 PM
    terry_amln terry_amln May 19, 2014 10:40 AM Flag

    lol Thanks Cathy " right about 18...can't believe I got it by kvnmcdd •Apr 4, 2014
    I was all back in on Monday..(APR 2 @ 19.76)))))).last lot bought and now I am adding. Last week research was a GAME CHANGER. I am excited.kvnmcdd
    kvnmcdd • May 13, 2014 3:59 PM
    campfund1 • May 13, 2014 4:01 PM
    alazoner • May 13, 2014 4:03 PM

  • terry_amln terry_amln May 16, 2014 3:31 PM Flag

    OK out 2500 x 0.51= $$$ Lunch money.I know I know these kids dont have a clue but from the looks of my whited out bd and thumbs- their Life is complete! ... the XXXX trade worked better Have more fun kids...
    Surfs up

  • terry_amln terry_amln May 16, 2014 3:14 PM Flag

    9 thumbs Impressive Mike ! 2500 @ .48 . options rush...

  • Reply to

    INSM is fairly valued 550-600M

    by terry_insm May 16, 2014 8:58 AM
    terry_amln terry_amln May 16, 2014 2:47 PM Flag

    Pete - No larger than 600 M total by 2020. I do expect another dilutive offering

  • terry_amln by terry_amln May 16, 2014 11:10 AM Flag

    Probably the owned bio in the business.@ 92% as usual no Baker selling, some insiders and the bakers shorts to play bank with the stock. Good Luck

  • Reply to

    NEWS: EMA Filing for CF and NTM in 2H 2014

    by labois4u May 12, 2014 6:15 PM
    terry_amln terry_amln May 15, 2014 9:29 PM Flag

    like the "filing!" some investors here are confused.The FDA will rule on if they can file not if the drug is to be approved. That process takes many months and if there is an expedited approval process then late next year is best case for NTM . As we have seen , the company has waited ? how many months just file in Europe after the P3 results in Europe. Then add 13 months till approval for CF - No Us sales looks like the FDA said - you took a chance and didnt do a US trial and the results were not compelling - so live with it - NO US. Good Luck

  • Reply to

    Institutions in charge-

    by terry_amln May 15, 2014 9:06 AM
    terry_amln terry_amln May 15, 2014 12:47 PM Flag

    INSM share price better hold ...else its 10.44 A sell on the news to the offering price of $10 is more probable- ..Good Luck.

  • Reply to

    Looks undervalued here

    by frankyassissi May 12, 2014 8:24 AM
    terry_amln terry_amln May 13, 2014 12:08 PM Flag

    thats me 900 shares@ 62 ..come to papa

  • Reply to

    Looks undervalued here

    by frankyassissi May 12, 2014 8:24 AM
    terry_amln terry_amln May 12, 2014 4:13 PM Flag

    closed above the 50 day $30.32- just in time for the shareholders meeting ; - )

  • Reply to

    Looks undervalued here

    by frankyassissi May 12, 2014 8:24 AM
    terry_amln terry_amln May 12, 2014 10:52 AM Flag

    Co speak this year 4th qtr. The million dollar question for Steve Burrill is when is the buyout? - )

  • terry_amln by terry_amln May 8, 2014 12:34 AM Flag

    A classic case of how to build a company. GHDX could be very profitable tomorrow but we know where they are going Good Luck.

GHDX
27.60+0.41(+1.51%)4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.